Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling

References

• Lee CK, Davies L, Wu YL, et al. Gefitinib or Erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J Natl Cancer Inst. 2017;109. doi: 10.1093/jnci/djw279.
   Google Scholar
• Kobayashi Y, Azuma K, Nagai H, et al. Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer. Mol Cancer Ther. 2017;16:357–364.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207–221.
   PubMed Web of Science ®Google Scholar
• Codony-Servat C, Codony-Servat J, Karachaliou N, et al. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget. 2017;8:47305–47316.
   PubMedGoogle Scholar
• Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12:589–597.
   PubMed Web of Science ®Google Scholar
• Fan W, Tang Z, Yin L, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 2011;71:4494–4505.
   PubMed Web of Science ®Google Scholar
• Li R, Hu Z, Sun SY, et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther. 2013;12:2200–2212.
   PubMed Web of Science ®Google Scholar
• Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018;3:108–117.
   PubMedGoogle Scholar
• Hu XY, Hou PF, Li TT, et al. The roles of Wnt/β-catenin signaling pathway related lncRNAs in cancer. Int J Biol Sci. 2018;14:2003–2011.
   PubMed Web of Science ®Google Scholar
• Fang Z, Chen W, Yuan Z, et al. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–542.
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen W, Xu Y, et al. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol. 2018;356:1–7.
   PubMed Web of Science ®Google Scholar
• Hong F, Gu W, Jiang J, et al. Anticancer activity of Polyphyllin I in nasopharyngeal carcinoma by modulation of lncRNA ROR and P53 signaling. J Drug Target. 2019;27:806–811.
   PubMed Web of Science ®Google Scholar
• Wei MM, Zhou GB. Long non-coding RNAs and their roles in non-small-cell lung cancer. Genom Proteom Bioinformatics. 2016;14:280–288.
   PubMed Web of Science ®Google Scholar
• Lu T, Wang Y, Chen D, et al. Potential clinical application of lncRNAs in non-small cell lung cancer. Onco Targets Ther. 2018;11:8045–8052.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma L, Xu F, et al. Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018;9:761–768.
   PubMed Web of Science ®Google Scholar
• Ma P, Zhang M, Nie F, et al. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer. Biomed Pharmacother. 2017;87:20–26.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yu DD, Hu Y, et al. Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray. Oncol Rep. 2016;35:3371–3386.
   PubMed Web of Science ®Google Scholar
• Su J, Zhang E, Han L, et al. Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15. Cell Death Dis. 2017;8:e2665.
   PubMed Web of Science ®Google Scholar
• Wang CH, Li YH, Tian HL, et al. Long non-coding RNA BLACAT1 promotes cell proliferation, migration and invasion in cervical cancer through activation of Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018; 22:3002–3009.
   PubMed Web of Science ®Google Scholar
• Niu G, Zhuang H, Li B, et al. Long noncoding RNA linc-UBC1 promotes tumor invasion and metastasis by regulating EZH2 and repressing E-cadherin in esophageal squamous cell carcinoma. J BUON. 2018;23:157–162.
   PubMed Web of Science ®Google Scholar
• Liao D, Lv G, Wang T, et al. Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma. Cancer Cell Int. 2018;18:47.
   PubMed Web of Science ®Google Scholar
• Dong Z, Wang Y. LncRNA BLACAT1 accelerates the proliferation and migration of osteosarcoma cells through regulating STAT3. Pathol Res Pract. 2019;215:571–579. pii: S0344-0338(18)30860-4.
   PubMed Web of Science ®Google Scholar
• Chen, W, Hang, Y, Xu, W, et al. BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small-cell lung cancer. J Cell Biochem. 2018. doi:10.1002/jcb.27548.
   Google Scholar
• Huang FX, Chen HJ, Zheng FX, et al. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy. Int J Oncol. 2019;54:339–347.
   PubMed Web of Science ®Google Scholar
• Wu X, Zheng Y, Han B, et al. Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–838.
   PubMed Web of Science ®Google Scholar
• Torigoe H, Shien K, Takeda T, et al. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci. 2018;109:1493–1502.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Yang C, et al. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Cell Cycle. 2018;17:1772–1783.
   PubMed Web of Science ®Google Scholar
• Zhang W, Cai X, Yu J, et al. Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer. Int J Oncol. 2018;53:527–538.
   PubMed Web of Science ®Google Scholar
• Wang B, Jiang H, Wang L, et al. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 2017;13:3494–3500.
   PubMed Web of Science ®Google Scholar
• Pan H, Jiang T, Cheng N, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget. 2016;7:49948–49960.
   PubMedGoogle Scholar
• Cheng N, Cai W, Ren S, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015;6:23582–23593.
   PubMedGoogle Scholar
• Wu Y, Yuan T, Wang WW, et al. Long noncoding RNA HOST2 promotes epithelial-mesenchymal transition, proliferation, invasion and migration of hepatocellular carcinoma cells by activating the JAK2-STAT3 signaling pathway. Cell Physiol Biochem. 2018;51:301–314.
   PubMedGoogle Scholar
• Yang C, Cai WC, Dong ZT, et al. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway. Gene. 2019;687:73–81.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Q, Wang Q, et al. NEAT1 paraspeckle promotes human hepatocellular carcinoma progression by strengthening IL-6/STAT3 signaling. Oncoimmunology. 2018;7:e1503913.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Zheng C, et al. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib. Cell Biol Int. 2018;42:1292–1299.
   PubMed Web of Science ®Google Scholar
• Makino Y, Yoon JH, Bae E, et al. Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma. Biochem Biophys Res Commun. 2017;484:269–277.
   PubMed Web of Science ®Google Scholar
• Phan AN, Hua TN, Kim MK, et al. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget. 2016;7:54702–54713.
   PubMedGoogle Scholar
• Shou J, You L, Yao J, et al. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Cancer Lett. 2016;379:124–133.
   PubMed Web of Science ®Google Scholar
• Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer. Lancet. 2016;387:1354–1356.
   PubMed Web of Science ®Google Scholar
• Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117:3846–3856.
   PubMed Web of Science ®Google Scholar
• Kim SM, Kwon OJ, Hong YK, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012;11:2254–2264.
   PubMed Web of Science ®Google Scholar